TY - JOUR
T1 - MCT8 deficiency in females
AU - Groeneweg, Stefan
AU - van Geest, Ferdy S
AU - van der Most, Floor
AU - Abela, Lucia
AU - Alfieri, Paolo
AU - Bauer, Andrew J
AU - Bertini, Enrico
AU - Cappa, Marco
AU - Çelik, Nurullah
AU - de Coo, Irenaeus F M
AU - Dolcetta-Capuzzo, Anna
AU - Dubinski, Ilja
AU - Granadillo, Jorge L
AU - Hoefsloot, Lies H
AU - Kalscheuer, Vera M
AU - van der Knoop, Marieke M
AU - Krude, Heiko
AU - McNerney, Kyle P
AU - Paone, Laura
AU - Peeters, Robin P
AU - Peters, Catherine
AU - Schuelke, Markus
AU - Schweizer, Ulrich
AU - Sprague, Jennifer E
AU - van Trotsenburg, A S Paul
AU - Wilpert, Nina-Maria
AU - Zanni, Ginevra
AU - van Zutven, Laura J C M
AU - Visser, W Edward
PY - 2025
Y1 - 2025
N2 - CONTEXT: Monocarboxylate transporter (MCT) 8 facilitates thyroid hormone transport across the blood-brain-barrier. Pathogenic variants in SLC16A2 cause MCT8 deficiency (Allan-Herndon-Dudley syndrome), characterized by intellectual and motor disability and abnormal thyroid function tests. MCT8 deficiency typically affects males due to its X-linked inheritance. Here, we report 8 female patients with heterozygous pathogenic variants in SLC16A2 who presented with variable neurocognitive impairment, behavioural problems and thyroid hormone function abnormalities. METHODS: We performed X-chromosome inactivation studies in female patients in whom heterozygous pathogenic variants in SLC16A2 were identified. The impact of SLC16A2 variants on thyroid hormone transport was assessed in transfected cells and patient-derived fibroblasts. RESULTS: In all patients (mean age 8.6 years, range 2.3-25 years) routine care genetic analyses identified heterozygous variants in SLC16A2 (p.(R445C), p.(N193I), p.(G276R), t(X;20) resulting in a breakpoint in intron 1, t(X;19) resulting in a breakpoint in SLC16A2, p.(I562Sfs566*), p.(G221R)). All missense variants showed substantially reduced MCT8-mediated thyroid hormone uptake in transiently transfected cells. X-chromosome inactivation studies in patient cells showed skewed X-inactivation in all 7 evaluated individuals. In 5 out of 7 evaluated cases, MCT8-mediated T3 uptake in patient-derived fibroblasts was impaired to a similar degree as in fibroblasts derived from male patients with MCT8 deficiency. CONCLUSIONS: Female patients with heterozygous pathogenic variants in SLC16A2 and skewed X-chromosome inactivation may present variable neuro(psycho)logical, behavioural and thyroid function test abnormalities. Female patients presenting with neurocognitive impairment and abnormal thyroid hormone function tests (low free T4 and/or high total T3 concentrations) should be tested for genetic variants in SLC16A2.
AB - CONTEXT: Monocarboxylate transporter (MCT) 8 facilitates thyroid hormone transport across the blood-brain-barrier. Pathogenic variants in SLC16A2 cause MCT8 deficiency (Allan-Herndon-Dudley syndrome), characterized by intellectual and motor disability and abnormal thyroid function tests. MCT8 deficiency typically affects males due to its X-linked inheritance. Here, we report 8 female patients with heterozygous pathogenic variants in SLC16A2 who presented with variable neurocognitive impairment, behavioural problems and thyroid hormone function abnormalities. METHODS: We performed X-chromosome inactivation studies in female patients in whom heterozygous pathogenic variants in SLC16A2 were identified. The impact of SLC16A2 variants on thyroid hormone transport was assessed in transfected cells and patient-derived fibroblasts. RESULTS: In all patients (mean age 8.6 years, range 2.3-25 years) routine care genetic analyses identified heterozygous variants in SLC16A2 (p.(R445C), p.(N193I), p.(G276R), t(X;20) resulting in a breakpoint in intron 1, t(X;19) resulting in a breakpoint in SLC16A2, p.(I562Sfs566*), p.(G221R)). All missense variants showed substantially reduced MCT8-mediated thyroid hormone uptake in transiently transfected cells. X-chromosome inactivation studies in patient cells showed skewed X-inactivation in all 7 evaluated individuals. In 5 out of 7 evaluated cases, MCT8-mediated T3 uptake in patient-derived fibroblasts was impaired to a similar degree as in fibroblasts derived from male patients with MCT8 deficiency. CONCLUSIONS: Female patients with heterozygous pathogenic variants in SLC16A2 and skewed X-chromosome inactivation may present variable neuro(psycho)logical, behavioural and thyroid function test abnormalities. Female patients presenting with neurocognitive impairment and abnormal thyroid hormone function tests (low free T4 and/or high total T3 concentrations) should be tested for genetic variants in SLC16A2.
KW - MCT8
KW - Monocarboxylate transporter 8
KW - neurocognitive impairment
KW - skewed X-chromosome inactivation
KW - thyroid hormone
KW - thyroid hormone transport
U2 - 10.1210/clinem/dgaf311
DO - 10.1210/clinem/dgaf311
M3 - Article
SN - 0021-972X
JO - Journal of Clinical Endocrinology & Metabolism
JF - Journal of Clinical Endocrinology & Metabolism
M1 - dgaf311
ER -